Membranose glomerulonephritis in the practice of a therapist


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Membranous glomerulonephritis (MGN) is characterized by diffuse thickening and changes in the structure of the basement membrane of the glomeruli due to subepithelial and intramembranous deposition of immune complexes and the deposition of matrix material produced by affected podocytes. As the most common cause of nephrotic syndrome in adults, MGN is divided into primary (idiopathic) and secondary forms. The primary task of examining a patient with newly diagnosed MGN is to exclude secondary causes of the disease. Primary MGN develops more often in young and middle-aged people. secondary MGN is more common in children. in mgn, it is necessary to test for the A2 phospholipase receptor (PLA2R1) antigen, anti-pla2R1 IgG antibodies and determine the number of cells in the glomerular infiltrate. persons of older age groups in the absence of deposits with anti-pla2R1 antibodies and in the presence of igG2 and iggi deposits need additional examination for the presence of a paraneoplastic process.

Full Text

Restricted Access

About the authors

Ilkhom T. Murkamilov

I.K. Akhunbaev Kyrgyz State Medical Academy; Kyrgyz-Russian Slavic University

Email: murkamilov.i@mail.ru
Cand. Sci. (Med.), Nephrologist, Deputy Associate Professor at the Department of Faculty Therapy

Ibragim S. Sabirov

Kyrgyz-Russian Slavic University

Email: sabirov_is@mail.ru
Dr. Sci. (Med.)., Professor, Head of the Department of Therapy № 2 in the specialty "General Medicine"

Viktor V. Fomin

Sechenov University

Email: fomin_vic@mail.ru
Dr. Sci. (Med.)., Professor, Corresponding Member of RAS, Head of the Department of Faculty Therapy № 1, N.F. Sklifosovsky Institute of Clinical Medicine, Vice-Rector for Clinical Work and Postgraduate Professional Education

Zh. A Murkamilova

Kyrgyz-Russian Slavic University

Email: murkamilovazh.t@mail.ru

Indira O. Kudaibergenova

I.K. Akhunbaev Kyrgyz State Medical Academy

Email: k_i_o2403@mail.ru
Dr. Sci. (Med.), Professor, Rector

Furkat A. Yusupov

Osh State University

Email: furcat_y@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Neurology, Neurosurgery and Psychiatry, Medical Faculty

References

  1. Бобкова И.Н., Камышова Е.С. Современный взгляд на лечение мембранозной нефропатии. Тер. архив. 2020;92(6):99-104. https://dx.doi.org/10.26442/00403660.2020.06.000676
  2. Добронравов В.А., Майер Д.А., Бережная О.В. и др. Мембранозная нефропатия в российской популяции. Тер. архив. 2017;6(89):21-9. https://dx.doi.org/10.17116/terarkh201789621-29
  3. Столяревич Е.С., Жилинская Т.Р., Варясин В.В. Морфологическая структура почечной патологии по данным пункционной биопсии почки. Клин. нефрология.2020;2:31-6. https://dx.doi.org/10.18565/nephrology.2020.2.31-36
  4. Cai Q., Hendricks A.R. Membranous nephropathy: A ten-year journey of discoveries.Seminars in Diagnostic Pathology. WB Saunders. 2020;37:3:116 20. https://doi.org/10.1053/j.semdp.2020.01.001
  5. Муркамилов И.Т., Сабиров И.С., Фомин В.В. и др. Мембранозный гломерулонефрит: современный взгляд на проблему и возможности терапии. Клин. нефрология.2020;1:53-60. https://dx.doi.org/10.18565/nephrology.2020.1.53-60
  6. Бобкова И.Н., Козловская Л.В., Цыгин А.Н., Шилов Е.М. Клинические рекомендации по диагностике и лечению мембранозной нефропатии. Нефрология. 2014;18(4):93-100.
  7. Бобкова И.Н., Кахсуруева П.А., Ставровская Е.В., Филатова Е.Е. Эволюция в понимании патогенеза идиопатической мембранозной нефропатии: от экспериментальных моделей к клинике. Альманах клинической медицины. 2017;45(7):553-64. https://doi.org/10.18786/2072-0505-2017-45-7-553-564.
  8. Батюшин М.М., Броновицкая Н.А., Синельник Е.А. и др. Опыт успешного применения ритуксимаба при резистентной к терапии мембранозной нефропатии. Южно-Российский журнал терапевтической практики. 2020;1(3):91-4. https://doi.org/10.21886/2712-8156-2020-1-3-91-94
  9. Тареева И.Е., Мухин Н.А., Шилов Е.М. Диагностика и лечение болезней почек. М., 2006.
  10. Rihova Z., Honsova E., Merta M., et al. Secondary membranous nephropathy - one center experience. Renal. Failure. 2005;27:4:397-402. https://doi.org/10.1081/JDI-65304.
  11. Lefaucheur C., Stengel B., Nochy D., et al. GN-PROGRESS study group membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int. 2006;70:1510-17. https://doi.org/10.1038/sj.ki.5001790.
  12. Бобылева И.А., Кахсуруева П. А., Камышова Е.С. и др. Изучение ассоциации вариантов гена рецептора фосфолипазы А2 М-типа (PLA2R1) с предрасположенностью к развитию идиопатической мембранозной нефропатии. Клин. фармакол. терапия. 2019;28(3):29-33. https://doi.org/10.32756/0869-5490-2019-3-29-33.
  13. Сиповский В.Г., Лебедев К.И. Структура первичных гломерулопатий среди взрослого населения Северо-Западного федерального округа России. Тихоокеанский медицинский журнал. 2016;61(4):35-7. https://doi.org/10.17238/PmJ1609-1175.2016.4.35-37.
  14. Стелье Т., Джоли Д., Ванилл Ф. и др. Клинико-патологическое многоцентровое исследование гломерулопатий, ассоциированных с саркоидозом. Нефрология. 2014;18(1):14-24.
  15. Berliner A.R., Haas M., Choi M.J. Sarcoidosis: the nephrologist’s perspective. Am J. Kidney Dis. 2006;48(5):856-70. https://doi.org/10.1053/j.ajkd.2006.07.022.
  16. Жигалов С.А., Марасаев В.В., Бажина О.В., Загородникова Н.В. Гломерулярные поражения почек при ревматоидном артрите. Клин. нефрология. 2013;6:42-5.
  17. Helin H.J., Korpela M.M., Mustonen J.T., Pasternack A.I. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis & Rheumatism: Off. J. Am. Coll. Rheumatol. 1995;38:2:242-47. https://doi.org/10.1002/art.1780380213.
  18. Nakano M., Ueno M., Nishi S., et al. Analysis of renal pathology and drug history in 158 Japanese patients with rheumatoid arthritis.Clin. Nephrol. 1998;50:3:154-60.
  19. Yoshida A., Morozumi K., Suganuma T., et al. Clinicopathological study of nephropathy in patients with rheumatoid arthritis. Ryumachi. [Rheumatism]. 1991;31:1:14-21.
  20. Meyer-Schwesinger C., Tomas N.M., Dehde S., et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int. 2020;97:5:913-19. https://doi.org/10.1016/j.kint.2019.10.022.
  21. Cai Q., Hendricks A.R. Membranous nephropathy: A ten-year journey of discoveries Seminars in Diagnostic Pathology. WB Saunders. 2020;37:3:116 20. https://doi.org/10.1053/j.semdp.2020.01.001
  22. Fujioka H., Koike T., Imamura T., et al. Mucoepidermoid carcinoma of parotid gland and membranous nephropathy-differentiation between sclerosing mucoepidermoid carcinoma with eosinophilia and Kimura’s disease. BMC. Nephrol. 2020;21(1):1-5. https://doi.org/10.1186/s12882-020-02030-1
  23. Okamoto M., Kitamura M., Sato S., et al. Life prognosis and renal relapse after induction therapy in Japanese patients with proliferative and pure membranous lupus nephritis. Rheumatol. 2020. https://doi.org/10.1093/rheumatology/keaa599
  24. Wang Q., Ruiz J.P., Hart PD. Case report: a man with untreated rheumatoid arthritis, cryoglobulinemic vasculitis, membranous nephropathy and pulmonary sarcoidosis. BMC. Nephrol. 2020;21(1):1-8. https://doi.org/10.1186/s12882-020-02161-5
  25. Kimoto M., Fukunaga N., Yamaguchi N., et al. A case of denosumab-associated membranous nephropathy in a patient with rheumatoid arthritis. CEN Case Reports. 2020;9(1):1-5. https://doi.org/10.1007/s13730-019-00414-3
  26. Nikolopoulou A., Teixeira C., Cook H.T., et al. Membranous nephropathy associated with viral infection. Clin. Kidney J. 2020. https://doi.org/10.1093/ckj/sfaa026
  27. Cattran D.C., Feehally J., Cook H.T., et al. Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int. Suppl. 2012;2(2):139-274. https://doi.org/10.1038/kisup.2012.9
  28. Мершер С., Форнони А. Патология подоцитов и нефропатия - роль сфинголипидов в гломерулярных болезнях. Нефрология. 2016;20(1):10-
  29. Шамитова Е.Н., Романов В.О. Подоцитарные маркеры в моче.Успехи современной науки и образования. 2016;11(6):107-10.
  30. Бобкова И.Н., Шестакова М.В., Щукина А.А. Диабетическая нефропатия - фокус на повреждение подоцитов. Нефрология. 2015;19(2):33-
  31. Бобкова И.Н., Щукина А.А., Шестакова М.В. Оценка уровней нефрина и подоцина в моче у больных сахарным диабетом. Нефрология. 2017;21(2):33-40. https://doi.org/10.24884/1561-6274-2017-21-2-33-40.
  32. Pisarek-Horowitz A., Fan X., Kumar S., et al. Loss of Roundabout Guidance Receptor 2 (Robo2) in Podocytes Protects Adult Mice from Glomerular Injury by Maintaining Podocyte Foot Process Structure. Am. J. Pathol. 2020; 190:4:799-816. https://doi.org/10.1016/j.ajpath.2019.12.009
  33. Faul C., Asanuma K., Yanagida-Asanuma E., et al. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 2007;17:9:428-37. https://doi.org/10.1016/j.tcb.2007.06.006
  34. Tsuji K., Kitamura S., Wada J. MicroRNAs as Biomarkers for Nephrotic Syndrome. Int. J. Mol. Sci. 2021;22(1):88. https://doi.org/10.3390/ijms22010088
  35. Hoxha E., Stah R.A.K., Reinhard L., et al. A new chemiluminescence immunoassay for phospholipase A2 receptor 1 autoantibodies allows early identification of autoantibody recurrence in patients with membranous nephropathy. Kidney Int. Reports. 2021. https://doi.org/10.1016/j.ekir.2020.12.034
  36. Dustin M.L., Olszowy M.W., Holdorf A.D., et al. A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts. Cell. 1998;94(5):667-77. https://doi.org/10.1016/S0092-8674(00)81608-6.
  37. Schiffer M., Mundel.P., Shaw A.S., et al. A novel role for the adaptor molecule CD2 -associated protein in transforming growth factory-induced apoptosis. J. Biol. Chem. 2004;279(35):37004-12.
  38. Случанко Н.Н., Гусев Н.Б. Белки семейства 14-3-3 и регуляция цито-скелета.Успехи биологической химии. 2010;50:69-116.
  39. Часовских Н.Ю., Рязанцева Н.В., Кайгородова Е.В. и др. Состояние системы МАР-КинАЗ JNK и р38 в мононуклеарных лейкоцитах крови при воспалении. Мед. иммунология. 2009;11(6):515-22.
  40. Yokota R., Bhunu B., Toba H., Intapad S. Sphingolipids and kidney disease: Possible role of preeclampsia and intrauterine growth restriction (IUGR). Kidney 360. 2021. Doi: https://doi.org/10.34067/KID.0006322020.
  41. Мершер С., Форнони А. Патология подоцитов и нефропатия - роль сфинголипидов в гломерулярных болезнях. Нефрология. 2016;20(1):10-
  42. Savostyanov K., Pushkov A., Zhurkova N., et al. Selective screening for nephropathic cystinosis among high-risk contingents of the children population in Russia. Mol. Genet. Metab. 2020;129(2):S144.
  43. Савостьянов К.В. Оптимизация молекулярной диагностики редких наследственных болезней у российских пациентов. Дисс. док т. биол. наук. М., 2020.
  44. Сиповский В.Г., Неворотин А.И., Авсиевич И.В., Смирнов А.В. Ультраструктурное исследование альтерации подоцитов при непролиферативных гломерулопатиях. Архив патологии. 2019;81(3):51-8. https://doi.org/10.17116/patol20198103151.
  45. Cara-Fuentes G., Smoyer W.E. Biomarkers in pediatric glomerulonephritis and nephrotic syndrome. Pediatr. Nephrol. 2021. С.1-15. https://doi.org/10.1007/s00467-020-04867-y.
  46. Fischer E., Mougenot B., Callard P., et al. Abnormal expression of glomerular basement membrane laminins in membranous glomerulonephritis. Nephr. Dyal. Transp. 2000;15(12):1956-64. https://doi.org/10.1093/ndt/15.12.1956
  47. Батюшин М.М., Пасечник Д.Г. Ламинины в структуре гломерулярной базальной мембраны. Нефрология. 2016;20(5):9-15.
  48. Raychowdhury R., Zheng G., Brown D., McCluskey R.T. Induction of Heymann nephritis with a gp330/megalin fusion protein. Am. J. Pathol. 1996;148:1613-23.
  49. Петросян Э.К., Паунова С.С., Длин В.В., Шумилов П.В. Проект современной классификации гломерулонефрита у детей. Педиатрия. 2015;94(3):188-95. @@Игнатова М.С., Длин В.В. Нефротический синдром: прошлое, настоящее и будущее. Рос. вестн. перинатологии и педиатрии. 2017;62:(6):29-44. https://doi.org/10.21508/1027-4065-2017-62-6-29-44.
  50. Moroni G., Ponticelli C. Secondary Membranous Nephropathy. A Narrative Review. Front. Med. 2020;7:928. https://doi.org/10.3389/fmed.2020.611317.
  51. Кузьмин О.Б., Жежа В.В., Белянин В.В., Ландарь Л.Н. Гломерулярная гипертензия: молекулярные механизмы повреждения подоцитов и мезангиальных клеток. Нефрология. 2016;20(4):31-9. https://doi.org/10.24884/1561-6274-2016-20-4-46-50.
  52. Cardoso V.G., Gongalves G.L., Costa-Pessoa J.M., et al. Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress/PKC-5/ p38 MAPK pathway activation and trough increased Na+/H+ exchanger isoform 1 activity. BMC. Nephrol. 2018;19(1):1-12. https://doi.org/10.1186/s12882-018-0968-4.
  53. Ruiz-Ortega M., Lorenzo O., Suzuki Y., et al. Proinflammatory actions of angiotensins. Curr. Opin. Nephrol. Hypertens. 2001;10(3):321-29.
  54. Ozeki T., Nagata M., Katsuno T., et al. Nephrotic syndrome withfocal segmental glomerular lesions unclassified by Columbia classification; Pathology and clinical implication. Plos one. 2021;16(1):e0244677. https://doi.org/10.1371/journal.pone.0244677.
  55. Yang W.Y., Chen L.C., Jhuang Y.T., et al. Injection of Hybrid 3D Spheroids Composed of Podocytes, Mesenchymal Stem Cells, and Vascular Endothelial Cells into the Renal Cortex Improves Kidney Function and Replenishes Glomerular Podocytes. Bioengineer. Translat. Med. 2021:e10212. https://doi.org/10.1002/btm2.10212.
  56. Lwezaula B.F., Ameh O.I., Ekrikpo U.E., et al. Diagnostic performance of glomerular PLA2R and THSD7A antibodies in biopsy confirmed primary membranous nephropathy in South Africans. BMC. Nephrol. 2021;22(1):1-8. https://doi.org/10.1186/s12882-020-02216-7.
  57. Padmavathi K., Senthilkumar A.V., Dutta A. Hybrid Feature Selection Method for Predicting the Kidney Disease Membranous Nephropathy. Innovations in Computational Intelligence and Computer Vision. Springer, Singapore. 2021:472-8. https://doi.org/10.1007/978-981-15-6067-5_53.
  58. Джумабаева Б.Т., Бирюкова Л.С. Новые аспекты патофизиологии и патоморфологии поражений почек при злокачественных опухолях. Клин. онкогематология. 2015;8(4):390-6.
  59. Debiec H., Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N. Engl. J. Med. 2011;364(7):689-90.
  60. Бобылева И.А., Кахсуруева П.А., Камышова Е.С. и др. Клинико генетические особенности идиопатической мембранозной нефропатии у российских пациентов. Клин. нефрология. 2019;3(11):31-6. https://doi.org/10.18565/nephrology.2019.3.31-36.
  61. Maifata S.M.A., Hod R., Zakaria F., Ghani F.A. Role of Serum and Urine Biomarkers (PLA2R and THSD7A) in Diagnosis, Monitoring and Prognostication of Primary Membranous Glomerulonephritis. Biomolecul. 2020;10(2):319. https://doi.org/10.3390/biom10020319.
  62. Nikolopoulou A., Teixeira C., Cook H.T., et al. Membranous nephropathy associated with viral infection.Clin. Kidney J. 2020;14(3):876-83. https://doi.org/10.1093/ckj/sfaa026
  63. Qin W., Beck LHJr., Zeng C., et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J. Am. Soc. Nephrol. 2011;22(6):1137-43. https://doi.org/10.1681/ASN.2010090967
  64. Knehtl M., Debiec H., Kamgang P., et al. A case of phospholipase A(2) receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis. Am. J. Kidney Dis. 2011;57(1):140-43. https://doi.org/10.1053/j.ajkd.2010.09.015
  65. Scadding J.G. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases afterfiveyears’ observation. Br. Med. J. 1961;2(5261):1165-72. https://doi.org/10.1136/bmj.2.5261.1165
  66. Hanset N., Aydin S., Demoulin N., et al. Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study. Am. J. Kidney Dis. 2020;76(5):624-35. https://doi.org/10.1053/j.ajkd.2020.04.013
  67. Sethi S., Debiec H., Madden B., et al. Neural epidermal growth factorlike 1 protein (NELL-1) associated membranous nephropathy. Kidney Int. 2020;97(1):163-74. https://doi.org/10.1016/j.kint.2019.09.014
  68. Zhang D., Zhang C., Bian F., et al. Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review.The Int. J. Biol. Markers. 2019;34(4):406-13. https://doi.org/10.1177/1724600819882698
  69. Lou Y., Gao D., Guo Q., et al. Changes in Clinicopathological Characteristics of Patients with Idiopathic Membranous Nephropathy: A Single-Center Retrospective Study. Iranian Red Crescent Med. J. 2020;22(5):e97452. http://dx.doi.org/10.5812/ircmj.97452
  70. Rao S.J., Shen Q., Wang H.M., et al. The association of anti-PLA2R with clinical manifestations and outcomes in idiopathic membranous nephropathy: a meta-analysis. Int. Urol. Nephrol. 2020;52(11):2123-33. https://doi.org/10.1007/s11255-020-02588-7.
  71. Couser W.G. The pathogenesis of human membranous nephropathy: we are (almost) there. Kidney Int. 2020;97(5):849-52. https://doi.org/10.1016/j.kint.2020.01.037.
  72. Pozdzik A., Brocheriou I., David C., et al. Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management. Biomed Res. Int. 2018;2018:6281054. https://doi.org/10.1155/2018/6281054.
  73. Xian L., Dong D., Luo J., et al. Expression of THSD7A in neoplasm tissues and its relationship with proteinuria. BMC. Nephrol. 2019;20(1):332. https://doi.org/10.1186/s12882-019-1489-5.
  74. Кузнецова С.А., Крылов А.В., Киселева Е.П. Иммунорегуляторные свойства тромбоспондина-1, компонента внеклеточного матрикса и ингибитора ангиогенеза. Мед. иммунология. 2008;10(6):499-506. https://doi.org/10.15789/1563-0625-2008-6-499-506.
  75. Narizhneva N.V., Razorenova O.V., Podrez E.A., et al. Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J. 2005;19(9):1158-60. https://doi.org/10.1096/fj.04-3310fje.
  76. Ruscica M., Ruscica M., Zimetti F., et al. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia. Pharmacological Res. 2020;153:104653. https://doi.org/10.1016/j.phrs.2020.104653.
  77. Lai H., Chen A., Cai H., et al. Podocyte and endothelial-specific elimination of BA MB I. identifies differential transforming growth fact or-в pathways contributing to diabetic glomerulopathy. Kidney Int. 2020;98(3):601-14. https://doi.org/10.1016/j.kint.2020.03.036.
  78. Tufro A., Veron D. VEGF and podocytes in diabetic nephropathy. Seminars in nephrology. WB Saunders. 2012;32(4):385-93. https://doi.org/10.1016/j.semnephrol.2012.06.010.
  79. Добронравов В.А., Лапин С.В., Лазарева Н.М., и др. Циркулирующие антитела к рецептору фосфолипазы А2 при первичной мембранозной нефропатии. Нефрология. 2012;16(4):39-44. https://doi.org/10.24884/1561-6274-2012-16-4-39-44.
  80. Detsika M.G., Lianos E.A. Regulation of Complement Activation by Heme Oxygenase-1 (HO-1) in Kidney Injury. Antioxidants. 2021;10(1):60. https://doi.org/10.3390/antiox10010060.
  81. AlYousef A., AlSahow A., AlHelal B., et al. Glomerulonephritis histopathological pattern change. BMC. Nephrol. 2020;21:1-7. https://doi.org/10.1186/s12882-020-01836-3.
  82. Sardhara J., Shukla M., Jamdar J., et al. Paraneoplastic nephrotic syndrome in a patient with planum sphenoidale meningioma. Asian J. Neurosurg. 2018;13(3):864-66. https://doi.org/10.4103/1793-5482.238080.
  83. Офицеров В.И. Подклассы иммуноглобулина G: возможности использования в диагностической практике.ЗАО Вектор-Бест: Кольцово. 2005. 25 с.
  84. Birkeland S.A., Storm H.H. Glomerulonephritis and malignancy: A population-based analysis. Kidney Int. 2003;63(2):716-21. https://doi.org/10.1046/j.1523-1755.2003.00771.x.
  85. Baslo S.A., idrisoglu H.A., Aral O., Oge A.E. CIDP and membranous nephropathy: a case with limited electrophysiological findings and a rare association. Neurological Sci. 2020:1-5. https://doi.org/10.1007/s10072-020-04612-1.
  86. Iio R., Akiyama S.I., Mitsumoto K., et al. Thrombotic thrombocytopenic purpura developed during the conservative treatment of anti-phospholipase A 2 receptor antibody-positive idiopathic membranous nephropathy: a case report. BMC. Nephrol. 2020;21(1):1-6. https://doi.org/10.1186/s12882-020-02086-z.
  87. Witte A.S., Burke J.F. Membranous glomerulonephritis associated with chronic progressive demyelinating neuropathy. Neurol. 1987;37:342-45.
  88. Prasad N.S., Tirumavalavan S., Fernando M. D-penicillamine-induced membranous nephropathy. Indian J. Nephrol. 2014;24(3):195-96. https://doi.org/10.4103/0971-4065.132024.
  89. Larsen C.P., Messias N.C., Silva F.G., et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod. Pathol. 2013;26(5):70915. https://doi.org/10.1038/modpathol.2012.207.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies